|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Since the shortcomings of tumor tissue detection are well known, the liquid biopsy is more appropriate to track T790M status.
|
31805270 |
2020 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Plasma T790M detection was associated with a larger median baseline tumor size (56 mm for T790M-positive vs 39 mm for T790M-negative; P < .0001) and the presence of extrathoracic disease (58% for M1b-positive vs 39% for M0-1a-positive; P = .002).
|
31769875 |
2020 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Multiplex genomic testing of pretreatment tumor tissue may thus provide a means of identifying patients likely to develop T790M-mediated TKI resistance and therefore inform treatment selection.
|
31710890 |
2020 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
DNAs from pretreatment tumor biopsy samples and re-biopsy samples were assessed to detect T790M by the Cobas EGFR Mutation Test v2 (Cobas) and for quantitating T790M by droplet digital polymerase chain reaction (ddPCR).
|
31751804 |
2020 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
|
31494653 |
2020 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Ultra-sensitive detection of tumor T790M mutation concerned 8% of EGFR-mutated TKI-naïve NSCLC patients and has a negative prognostic value only for T790M VAF over 1%.
|
31841714 |
2020 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This uncertainty reflects the fact that most prospective clinical trials of EGFR TKIs have been restricted to patients with tumor harboring common (Del19 or L858R) mutations.
|
31558282 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M coexisted with L858R mutation (8/11) more than with deletions in exon 19 (19del) mutation (3/11) in TKI-naive tumors, while 19del co-occurred as often as L858R in post-TKI tumors.
|
31463130 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, the median PFS (P=0.005) and OS (P=0.002) of patients carrying the EGFR exon 21 L858R mutation was significantly decreased in patients with tumors where ERβ1 cytoplasmic expression was high.
|
31289556 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI-sensitizing mutations.
|
30240852 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR T790M mutation, which conveys resistance to in the present study, [<sup>18</sup> F]FEWZ was assessed in vitro to determine efficacy relative to the starting compound and in vivo to measure the biodistribution and specificity of binding to EGFR wild-type, L858R and T790M bearing tumours.
|
31132309 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and for patients with T790M-positive advanced NSCLC whose disease has progressed on or after EGFR-TKI therapy.
|
30875094 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
NGS of plasma circulating cell-free tumor DNA shown that L858R mutation was no longer detectable and the copy number of MET dropped when the patient got remission.
|
30797494 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we evaluated the concordance between plasma and tumour tissues by simultaneously detecting EGFR L858R by ddPCR and LNA-dPNA PCR clamp in 132 tissues and matched plasma samples from patients with NSCLC.
|
30663747 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There was no difference for the proportion of the 2 most frequent EGFR mutations (exon 19 deletion and L858R mutation) (P=0.85) or KRAS-mutated codon (P=0.22) between tumors in younger or older patients.
|
30095461 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we report a case of emergent <i>MET</i> amplification detected in a tumor sample from a patient with NSCLC harboring EGFR L858R mutation after disease progression on erlotinib.
|
30881166 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Real-time PCR analysis showed that the right-sided tumor had an epidermal growth factor receptor (EGFR) mutation presenting as point mutation T790M in exon 20, while the left-sided tumor had a point mutation L858R in exon 21 of EGFR.
|
31426797 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR T790M mutation, which conveys resistance to in the present study, [<sup>18</sup> F]FEWZ was assessed in vitro to determine efficacy relative to the starting compound and in vivo to measure the biodistribution and specificity of binding to EGFR wild-type, L858R and T790M bearing tumours.
|
31132309 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and for patients with T790M-positive advanced NSCLC whose disease has progressed on or after EGFR-TKI therapy.
|
30875094 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There was no difference for the proportion of the 2 most frequent EGFR mutations (exon 19 deletion and L858R mutation) (P=0.85) or KRAS-mutated codon (P=0.22) between tumors in younger or older patients.
|
30095461 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we report a case of emergent <i>MET</i> amplification detected in a tumor sample from a patient with NSCLC harboring EGFR L858R mutation after disease progression on erlotinib.
|
30881166 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we evaluated the concordance between plasma and tumour tissues by simultaneously detecting EGFR L858R by ddPCR and LNA-dPNA PCR clamp in 132 tissues and matched plasma samples from patients with NSCLC.
|
30663747 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
NGS of plasma circulating cell-free tumor DNA shown that L858R mutation was no longer detectable and the copy number of MET dropped when the patient got remission.
|
30797494 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI-sensitizing mutations.
|
30240852 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M coexisted with L858R mutation (8/11) more than with deletions in exon 19 (19del) mutation (3/11) in TKI-naive tumors, while 19del co-occurred as often as L858R in post-TKI tumors.
|
31463130 |
2019 |